TP53 and neoplasm: Evidence supporting the crucial role of p53 in the anti-tumor immune response has driven interest in the clinical translation of therapies involving p53 activation to induce an immune response with or without immunotherapy (Meric-Bernstam et al., 2017; Chung et al., 2019; Fang et al., 2019; Zhou et al., 2021).